VD2173 epimer-1

• CAT Number: I040326
• Molecular Formula: C31H45N9O6S
• Molecular Weight: 671.81
• Purity: ≥95%
• Synonyms: (3S,6S,14S)-6-acetamido-N-[1-(1,3-benzothiazol-2-yl)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-3-(2-methylpropyl)-2,5,8-trioxo-1,4,9-triazacyclotetradecane-14-carboxamide
• InChI: InChI=1S/C31H45N9O6S/c1-17(2)15-22-28(45)38-21(10-6-7-13-34-25(42)16-23(29(46)39-22)36-18(3)41)27(44)37-20(11-8-14-35-31(32)33)26(43)30-40-19-9-4-5-12-24(19)47-30/h4-5,9,12,17,20-23H,6-8,10-11,13-16H2,1-3H3,(H,34,42)(H,36,41)(H,37,44)(H,38,45)(H,39,46)(H4,32,33,35)/t20?,21-,22-,23-/m0/s1
• InChIKey: IWSNQHXPYYMOLJ-KVROEHFOSA-N
• SMILES: CC(C)CC1C(=O)NC(CCCCNC(=O)CC(C(=O)N1)NC(=O)C)C(=O)NC(CCCN=C(N)N)C(=O)C2=NC3=CC=CC=C3S2

VD2173 epimer-1 (Cat No.: I040326)is a stereoisomeric form of VD2173, a chemically modified core analog of tenofovir, developed for treating hepatitis B virus (HBV) infection. VD2173 epimer-1 retains antiviral activity by targeting HBV reverse transcription but with altered stereochemistry, potentially affecting its pharmacokinetics, potency, or selectivity. It is investigated for enhanced liver targeting and reduced systemic exposure. As part of epimer exploration, it aids in understanding structure–activity relationships (SAR) and optimizing next-generation nucleotide analogs for chronic hepatitis B therapy.

Reference

[1]. Damalanka VC, et, al. Macrocyclic Inhibitors of HGF-Activating Serine Proteases Overcome Resistance to Receptor Tyrosine Kinase Inhibitors and Block Lung Cancer Progression. J Med Chem. 2021 Dec 23;64(24):18158-18174.
[Content Brief]